Ligand Pharmaceuticals Incorporated (FRA:LGDN)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	139.38	72.31	22.95	45.01	19.52	47.62
Short-Term Investments	525.15	183.86	147.36	166.86	321.59	363.57
Cash & Short-Term Investments	664.52	256.17	170.31	211.87	341.11	411.19
Cash Growth	202.55%	50.41%	-19.62%	-37.89%	-17.04%	-61.57%
Accounts Receivable	57.56	38.38	32.92	30.42	85.45	56.85
Other Receivables	0.54	4.07	6.4	4.61	6.19	2.22
Receivables	58.1	42.45	39.31	35.04	91.65	59.06
Inventory	11.9	14.11	23.97	13.29	27.33	26.49
Prepaid Expenses	-	1.93	1.18	1.13	-	-
Restricted Cash	-	-	-	-	-	0.34
Other Current Assets	19.4	16.9	2.66	2.27	4.67	3.48
Total Current Assets	753.92	331.56	237.43	263.6	464.75	500.56
Property, Plant & Equipment	11.08	24.81	25.06	27.49	32.6	37.17
Long-Term Investments	148.72	10.91	49.32	3	-	-
Goodwill	101.54	105.25	103.37	105.67	105.67	189.66
Other Intangible Assets	233.54	266.65	299.61	352.64	386.8	606.31
Long-Term Accounts Receivable	206.33	185.02	62.29	-	-	-
Long-Term Deferred Tax Assets	9.53	0.07	0.21	8.53	35.73	24.32
Other Long-Term Assets	12.12	17.51	9.92	1.74	272.03	4.27
Total Assets	1,477	941.77	787.22	762.67	1,298	1,362
Accounts Payable	3.68	5.23	2.43	5.31	8.4	3.78
Accrued Expenses	20.71	25.53	10.09	13.3	12.4	15.61
Current Portion of Long-Term Debt	-	-	-	76.7	-	-
Current Portion of Leases	1.09	1.29	0.41	0.72	1.41	8.48
Current Income Taxes Payable	1.28	1.2	-	-	-	-
Current Unearned Revenue	-	1.28	1.22	0.36	0.65	29.44
Other Current Liabilities	3.78	2.58	2.63	2.43	18.8	42.8
Total Current Liabilities	30.54	37.11	16.78	98.81	41.67	100.11
Long-Term Debt	445.49	-	-	-	320.72	442.29
Long-Term Leases	4.42	5.86	5.77	10.34	2.31	5.76
Long-Term Unearned Revenue	-	18.18	15.14	0.04	-	-
Long-Term Deferred Tax Liabilities	22.67	32.52	31.62	30.62	30.86	64.6
Other Long-Term Liabilities	23.48	17.65	16.98	25.37	80.88	40
Total Liabilities	526.6	111.34	86.3	165.18	476.43	652.76
Common Stock	0.02	0.02	0.02	0.02	0.02	0.02
Additional Paid-In Capital	362.61	337.38	198.7	147.59	372.97	318.36
Retained Earnings	578.22	498.98	503.02	450.86	449.09	391.95
Comprehensive Income & Other	9.32	-5.94	-0.82	-0.98	-0.92	-0.8
Total Common Equity	950.17	830.44	700.91	597.49	821.16	709.53
Shareholders' Equity	950.17	830.44	700.91	597.49	821.16	709.53
Total Liabilities & Equity	1,477	941.77	787.22	762.67	1,298	1,362
Total Debt	451	7.15	6.18	87.75	324.44	456.53
Net Cash (Debt)	213.53	249.01	164.13	124.12	16.66	-45.34
Net Cash Growth	0.58%	51.72%	32.23%	644.83%	-	-
Net Cash Per Share	10.96	13.61	9.24	7.36	0.97	-2.69
Filing Date Shares Outstanding	19.68	19.26	17.71	17.08	16.85	16.61
Total Common Shares Outstanding	19.66	19.11	17.56	16.95	16.77	16.08
Working Capital	723.38	294.45	220.65	164.79	423.09	400.45
Book Value Per Share	48.34	43.46	39.92	35.25	48.97	44.13
Tangible Book Value	615.1	458.54	297.94	139.18	328.69	-86.45
Tangible Book Value Per Share	31.29	24.00	16.97	8.21	19.60	-5.38
Machinery	-	8.72	7.78	15.16	14.34	15.72
Construction In Progress	-	4.22	4.12	-	-	-
Leasehold Improvements	-	10.46	10.36	7.45	5.27	3.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.